Company intelligence / Profile preview

Imugene

Sydney, New South Wales, Australiaimugene.com ↗

Overview

Imugene has a diversified pipeline of five unique clinical-stage assets across four proprietary platforms. Notably:

HER-Vaxx has shown promise in gastric cancer.
PD1-Vaxx targets NSCLC and colorectal cancers.
VAXINIA received FDA Fast Track Designation for bile tract cancers; early results include a complete response lasting over 620 days in one patient. The company’s programs are progressing through various stages of clinical development with no major safety concerns reported to date.

Therapeutic areas: Oncology
Modalities: B-cell peptide vaccinesoncolytic viruses (genetically engineered chimeric orthopoxvirus)immunotherapies
Industry: Biotech

8 assets

7 more assets in the full pipeline.

City of Hope National Medical CenterMayo ClinicOhio State UniversityCollaborations/licensing agreements for core technologies.

Beyond the preview

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Follow clinical development from trial design and recruitment through results.

Explore licensing agreements, acquisitions, and the assets behind each deal.

Trace financing activity and the investors behind a company’s development.

Compare peer pipelines by target, modality, and therapeutic area.

Explore technology platforms and the patent landscape around relevant assets.

Connect company news and source material to the questions you’re investigating.

See how Gosset can support your research on Imugene.